deferasirox has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S | 1 |
| Agarwal, MB | 1 |
1 review(s) available for deferasirox and Cardiovascular Diseases
| Article | Year |
|---|---|
Deferasirox: oral, once daily iron chelator--an expert opinion.
Topics: Benzoates; Cardiovascular Diseases; Chelating Agents; Deferasirox; Expert Testimony; Hemosiderosis; Humans; Iron; Liver; Thalassemia; Triazoles | 2010 |
1 other study(ies) available for deferasirox and Cardiovascular Diseases
| Article | Year |
|---|---|
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles | 2016 |